Condition

Advanced Cholangiocarcinoma (2)

Advanced or Metastatic Solid Tumor (1)

Colorectal Cancer (1)

FGFR2 Fusions (1)

FGFR2 Gene Rearrangements (1)

Gene Rearrangement (1)

Non-small Cell Lung Cancer (1)

Pancreatic Ductal Adenocarcinoma (1)

Soft Tissue Sarcoma (1)

Overall Status

Recruiting (2)

Active, not recruiting (1)

Not yet recruiting (1)

Phase

phase 3 (2)

phase 1 (1)

phase 2 (1)

Sponsor

Taiho Oncology, Inc. (2)

Institut National de la Sante Et de la Recherche Medicale, France (1)

Taiho Pharmaceutical Co., Ltd. (1)

Collaborator

Commissariat A L'energie Atomique (1)

EUCLID Clinical Trial Platform (1)

Institut Bergonie (1)

Plateforme labellisee Inca - Hopital Europeen Georges Pompidou, Paris (1)

Plateforme labellisee Inca - Institut Bergonie, Bordeaux (1)

Study Documents

Intervention Type

drug (4)

combination product (1)

other (1)

Funder Type

Industry (3)

Other (1)

Study Type

Interventional (4)

tas-120

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer Trial in Tokyo (AB122, TAS-116, TAS-120)

Recruiting

Advanced or Metastatic Solid Tumor
+3 more

AB122
+3 more

Tokyo, Japan

A site selected by Taiho Pharmaceutical Co., Ltd.

Aug 5, 2022

Advanced Cholangiocarcinoma, FGFR2 Fusions, Gene Rearrangement Trial (TAS-120)

Not yet recruiting

Advanced Cholangiocarcinoma
+2 more

TAS-120

(no location specified)

Feb 3, 2023

Soft Tissue Sarcoma Trial in France (drug, combination product, other)

Recruiting

Soft Tissue Sarcoma

Nilotinib
+10 more

Bordeaux, France
+17 more

Oct 4, 2022

Advanced Cholangiocarcinoma, FGFR2 Gene Rearrangements Trial in Worldwide (TAS-120, Cisplatin/Gemcitabine)

Active, not recruiting

Advanced Cholangiocarcinoma
FGFR2 Gene Rearrangements

TAS-120
Cisplatin/Gemcitabine

Albuquerque, New Mexico
+100 more

Feb 1, 2023